117 related articles for article (PubMed ID: 25486962)
1. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Quesada AE; Rios A; Brown RE; Nguyen ND
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
[No Abstract] [Full Text] [Related]
2. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
4. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A
Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577
[No Abstract] [Full Text] [Related]
5. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
9. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Furtado M; Johnson R; Kruger A; Turner D; Rule S
Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and panobinostat combination is effective against PTCL.
Phipps C; Mok SJ; Ang AL; Goh YT; Tan D
Leuk Res; 2012 Jun; 36(6):e128-30. PubMed ID: 22444688
[No Abstract] [Full Text] [Related]
11. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
[No Abstract] [Full Text] [Related]
13. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
[No Abstract] [Full Text] [Related]
15. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and treatment of peripheral T-cell lymphoma].
Suzumiya J; Moriyama I; Kawakami K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():519-24. PubMed ID: 23134009
[No Abstract] [Full Text] [Related]
17. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
Toya T; Nannya Y; Hangaishi A; Shiseki M; Shimoyama T; Sakamaki H; Motoji T; Usuki K; Nakamura F; Kurokawa M
Leuk Lymphoma; 2016; 57(4):961-4. PubMed ID: 26366623
[No Abstract] [Full Text] [Related]
18. Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.
Wilcox RA
Lancet Haematol; 2018 May; 5(5):e182-e183. PubMed ID: 29703333
[No Abstract] [Full Text] [Related]
19. Loss of CD3 and TCRγδ expression in a relapsed hepatosplenic T-cell lymphoma.
Hodkoff A; Bentley P; Xu X
Leuk Lymphoma; 2018 Feb; 59(2):479-481. PubMed ID: 28573906
[No Abstract] [Full Text] [Related]
20. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
